R.S. McLaughlin Durham Regional Cancer Centre, Oshawa, and Department of Oncology, Queen's University, Kingston, ON.
Department of Pharmacy, Centre hospitalier de l'Université de Montréal, and Faculty of Pharmacy, University of Montreal, Montreal, QC.
Curr Oncol. 2014 Feb;21(1):19-26. doi: 10.3747/co.21.1740.
Anaplastic lymphoma kinase (ALK) rearrangements have been identified as key oncogenic drivers in a small subset of non-small-cell lung cancers (nsclcs). Small-molecule Alk kinase inhibitors such as crizotinib have transformed the natural history of nsclc for this subgroup of patients. Because of the prevalence of nsclc, ALK-positive patients represent an important example of the paradigm for personalized medicine. Although Alk inhibitors such as crizotinib are well tolerated, there is a potential for adverse events to occur. Proactive monitoring, treatment, and education concerning those adverse events will help to optimize the therapeutic index of the drugs. The present review summarizes the management of treatment-related adverse events that can arise with Alk inhibitors such as crizotinib.
间变性淋巴瘤激酶（ALK）重排已被确定为一小部分非小细胞肺癌（nsclc）中的关键致癌驱动因素。小分子ALK 激酶抑制剂，如克唑替尼，已经改变了这组患者的 nsclc 自然史。由于 nsclc 的普遍性，ALK 阳性患者代表了个性化医学范例的一个重要例子。尽管 Alk 抑制剂，如克唑替尼，耐受性良好，但仍有可能发生不良反应。主动监测、治疗和教育这些不良反应将有助于优化药物的治疗指数。本综述总结了克唑替尼等 Alk 抑制剂治疗相关不良反应的管理。
